[1] 中国心血管病风险评估和管理指南编写联合委员会. 中国心血管病风险评估和管理指南[J]. 中国循环杂志, 2019, 34(1):4-28. doi:  10.3969/j.issn.1000-3614.2019.01.002
[2] MORAN A, GU D F, ZHAO D, et al. Future cardiovascular disease in China: Markov model and risk factor scenario projections from the coronary heart disease policy model-China[J]. Circ Cardiovasc Qual Outcomes,2010,3(3):243-252. doi:  10.1161/CIRCOUTCOMES.109.910711
[3] 脑卒中防治系列指导规范编审委员会. 中国缺血性脑卒中血脂管理指导规范[J]. 实用心脑肺血管病杂志, 2015, 23(4):117.
[4] BAIGENT C, KEECH A, KEARNEY PM, et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90, 056 participants in 14 randomised trials of statins[J]. Lancet,2005,366:1267-1278. doi:  10.1016/S0140-6736(05)67394-1
[5] 何瑞, 徐志猛, 王来, 等. 他汀相关肌肉症状的研究进展[J]. 药学进展, 2020, 44(4):303-312.
[6] BAI X, ZHANG B, WANG P, et al. Effects of SLCO1B1 and GATM gene variants on rosuvastatin-induced myopathy are unrelated to high plasma exposure of rosuvastatin and its metabolites[J]. Acta Pharmacol Sin,2019,40(4):492-499. doi:  10.1038/s41401-018-0013-y
[7] 王婧, 赵帅, 王建欣. 缺血性脑卒中患者SLCO1B1和APOE基因多态性对阿托伐他汀疗效和安全性的影响[J]. 中国医院药学杂志, 2020, 40(16):1749-1754.
[8] CHOUINARD-WATKINS R, PLOURDE M. Fatty acid metabolism in carriers of apolipoprotein E epsilon 4 allele: is it contributing to higher risk of cognitive decline and coronary heart disease? Nutrients,2014,6(10):4452-4471. doi:  10.3390/nu6104452
[9] ZHANG Y, WEI DD, YUAN R, et al. Effects of APOE gene polymorphismon the efficacy of the atorvastatin in the treatment of hyperlipidemia[J]. Natl Med J China(中华医学杂志),2017,97(4):291-294.
[10] KIRAC D, BAYAM E, DAGDELEN M, et al. HMGCR and APOE mutations may cause different responses to lipid lowering statin therapy[J]. Cell Mol Biol (Noisy-le-grand),2017,63(10):43-48. doi:  10.14715/cmb/2017.63.10.6